Form 4: Regulus Therapeutics Director Kathryn J. Collier Acquires Stock Options

Director Kathryn J. Collier acquired 30,000 stock options in Regulus Therapeutics on May 16, 2024, as part of the company's Non-Employee Director's Compensation policy.

Summary

• Kathryn J. Collier, a director of Regulus Therapeutics Inc., reported a transaction involving derivative securities.
• On May 16, 2024, Collier acquired 30,000 stock options with an exercise price of $2.01.
• These options were granted pursuant to the company's Non-Employee Director's Compensation policy.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Collier directly owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard compensation practices, indicating stability and alignment of interests. There are no red flags or negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies to align management's interests with those of shareholders. Stock options are a typical component of compensation packages for directors and executives in the biotechnology industry.

Comparison to Industry Standards

• Granting stock options to directors is a common practice among publicly traded companies, especially in the biotech sector.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals also use stock options as part of their director compensation packages.
• The vesting schedule of one year is fairly standard, aligning with typical industry practices for incentivizing long-term commitment.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with those of the shareholders.
• Employees: The transaction does not directly impact employees.
• The transaction does not directly impact customers, suppliers, or creditors.

Key Dates